Skip to main content
. Author manuscript; available in PMC: 2021 Nov 11.
Published in final edited form as: Cell Host Microbe. 2020 Aug 11;28(5):699–711.e7. doi: 10.1016/j.chom.2020.07.008

Figure 7. RRV-12 Improves RRV-Induced Clinical Disease and Reduces Viral RNA Burden When Given Therapeutically in WT Mice.

Figure 7.

(A) 3-week-old WT C57BL/6J mice were inoculated with 103 FFU of RRV strain T48 before administration of 100-μg antibody by intraperitoneal injection at 24 hpi. Mice were then weighed each day over the course of 18 days and assigned a clinical score based on grip strength, gait, and righting reflex. Two independent experiments were performed, for a total of n = 7–8 mice in each antibody group. Statistical analysis was performed using a Student’s t test of area under the curve analysis (****p < 0.0001).

(B) 18 dpi, the spleen, ipsilateral and contralateral gastrocnemius, quadriceps, and ankle tissues were collected following extensive perfusion with PBS. Viral RNA was quantified through qRT-PCR and statistical analysis was performed using a Mann-Whitney test (*p < 0.05, **p < 0.01, ***p < 0.001).